Evidence map›Paper›PMID 36873419›Full record

ArticleJHEP reports : innovation in hepatology2023

Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis.

Yuki Yamashita, Takeji Umemura, Takefumi Kimura, Satoru Joshita, Junko Hirohara, Toshiaki Nakano, Atsumasa Komori, Atsushi Tanaka

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Gastro hep advances · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. The treatment of primary biliary cholangitis: from shadow to light.Therapeutic advances in gastroenterology · 2024
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yuki YamashitaDepartment of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Takeji UmemuraDepartment of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Takefumi KimuraDepartment of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Satoru JoshitaDepartment of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Junko HiroharaThe Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Toshiaki NakanoThe Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Atsumasa KomoriClinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki, Japan.
Atsushi TanakaDepartment of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Shinshu University · JPKansai Medical University · JPNagasaki Medical Center · JPTeikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: The albumin-bilirubin (ALBI) score is calculated using serum levels of total bilirubin and albumin as a simple method to assess liver function. This study investigated the ability of baseline ALBI score/grade measurements to assess histological stage and disease progression in individuals with primary biliary cholangitis (PBC) in a large Japanese nationwide cohort. Methods: A total of 8,768 Japanese patients with PBC were enrolled between 1980 and 2016 from 469 institutions, among whom 83% received ursodeoxycholic acid (UDCA) only, 9% received UDCA and bezafibrate, and 8% were given neither drug. Baseline clinical and laboratory parameters were retrospectively retrieved and reviewed from a central database. Associations of ALBI score/grade with histological stage, mortality, and need for liver transplantation (LT) were evaluated using Cox proportional hazards models. Results: During the median follow-up period of 5.3 years, 1,227 patients died (including 789 from liver-related causes) and 113 underwent LT. ALBI score and ALBI grade were significantly associated with Scheuer's classification (both Conclusions: This large nationwide study of patients with PBC suggested that baseline measurements of ALBI grade were a simple non-invasive predictor of prognosis in PBC. Impact and implications: Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts. This study examined the ability of albumin-bilirubin (ALBI) score/grade to estimate histological findings and disease progression in PBC by means of a large-scale nationwide cohort in Japan. ALBI score/grade were significantly associated with Scheuer's classification stage. Baseline ALBI grade measurements may be a simple non-invasive predictor of prognosis in PBC.

Indexed as

ALBI, albumin-bilirubinALP, alkaline phosphataseAMA, anti-mitochondrial autoantibodyAUC, area under the ROC curveBZF, bezafibrateHR, hazard ratioLSM, liver stiffness measurementLT, liver transplantationM2BPGi, Mac-2-binding protein glycosylation isomerPBC, primary biliary cholangitispc, corrected pPrognosisROC, receiver-operating characteristicTransplantationUDCA, ursodeoxycholic acidULN, upper limit of normalUrsodeoxycholic acid

Identifiers

PMID36873419
PMCPMC9976453
OpenAlexW4312203925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.